Mallinckrodt PLC (MNK)
8.05
+0.20
(+2.55%)
USD |
NYAM |
Mar 24, 16:00
8.125
+0.08
(+0.93%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 106.03M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.2059 |
| Price to Book Value | 0.0573 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
PR Newswire
03/22 18:15
PR Newswire
03/21 20:58
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/28/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | -- | -- | -- | |
| 11/08/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2020 | 08:30 EST | Earnings Call | Q2 2020 | -- | -- | -- | |
| 08/04/2020 | -- | Results | Q2 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States. |
| URL | https://www.mallinckrodt.com |
| Investor Relations URL | https://ir.mallinckrodt.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
Ratings
Profile
Edit
| Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States. |
| URL | https://www.mallinckrodt.com |
| Investor Relations URL | https://ir.mallinckrodt.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| QHY.TO | 22546.00 USD | 0.06% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| MNK Tweets |